NEW YORK (GenomeWeb News) — UK-based synthetic polymer company Chromatide said today that it has received an undisclosed second round of financing from Enterprise Ventures and Alliance Fund Managers, both of which invested in it in 2007.

Chromatide, which plans to use the money to continue expanding its IP portfolio, said that since the first investment it has "successfully delivered on a range of technical and commercial" milestones.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.